Exelixis/$EXEL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Exelixis
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
- Ticker
- $EXEL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,077
- Headquarters
- Alameda, United States
- Website
- www.exelixis.com
Exelixis Metrics
BasicAdvanced
$17B
20.73
$3.35
0.47
-
Price and volume
Market cap
$17B
Beta
0.47
52-week high
$72.10
52-week low
$36.00
Average daily volume
2.2M
Financial strength
Current ratio
3.209
Quick ratio
2.963
Long term debt to equity
0.088
Total debt to equity
0.088
Profitability
EBITDA (TTM)
1,031.901
Gross margin (TTM)
96.26%
Net profit margin (TTM)
35.45%
Operating margin (TTM)
40.21%
Effective tax rate (TTM)
16.95%
Revenue per employee (TTM)
$2,320,000
Management effectiveness
Return on assets (TTM)
23.52%
Return on equity (TTM)
44.32%
Valuation
Price to earnings (TTM)
20.727
Price to revenue (TTM)
7.103
Price to book
9.37
Price to tangible book (TTM)
9.7
Price to free cash flow (TTM)
15.496
Free cash flow yield (TTM)
6.45%
Free cash flow per share (TTM)
4.478
Growth
Revenue change (TTM)
9.12%
Earnings per share change (TTM)
40.87%
3-year revenue growth (CAGR)
12.06%
10-year revenue growth (CAGR)
35.04%
3-year earnings per share growth (CAGR)
127.03%
10-year earnings per share growth (CAGR)
18.29%
What the Analysts think about Exelixis
Analyst ratings (Buy, Hold, Sell) for Exelixis stock.
Analyst projections of the future price of Exelixis stock.
Bulls say / Bears say
CABOMETYX continued to deliver strong growth: US product revenue rose to $604.9 million in Q3 2026 from $542.9 million a year earlier, with higher sales volume and net prices supporting cash generation. (Exelixis)
Zanzalintinib offers a potential second growth engine: its STELLAR-303 trial showed a statistically significant overall-survival benefit in the full study population, and the FDA is reviewing the drug for colorectal cancer. Approval could open a new market, although the decision is now due in March 2027. (Exelixis)
The pipeline could broaden beyond colorectal cancer: zanzalintinib is also in pivotal trials for kidney and neuroendocrine cancers, with STELLAR-304 results expected in the first quarter of 2027. Success in those studies could support further indications for the next potential franchise drug. (Exelixis)
STELLAR-303 failed to show a statistically significant overall-survival benefit in its co-primary subgroup of patients without active liver metastases. That weaker result could complicate FDA review or limit the eventual label. (Fierce Biotech)
The FDA extended its review of zanzalintinib in colorectal cancer by three months, to 3 March 2027, after Exelixis submitted updated safety and efficacy data that the agency deemed a major amendment. The delay pushes back a potential launch and adds regulatory uncertainty. (Reuters)
CABOMETYX remains the main revenue driver, while generic cabozantinib products have agreed launch dates from January 2031 and a proposed alternative formulation could enter from December 2030 if approved. This creates a defined risk to the company's largest revenue stream before a successor franchise is established. (Exelixis)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
Exelixis Financial Performance
Revenues and expenses
Exelixis Earnings Performance
Company profitability
Upcoming events
No upcoming events
Exelixis News
AllArticlesVideos
Funds containing Exelixis
AllUSDEURGBP
Fund name | Fund size | $EXEL weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 1.43% |
iShares Healthcare Innovation€2B78 | $1.2B | 1.43% |
iShares Healthcare Innovation$HEAL | $1.3B | 1.43% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 1.04% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 1.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.